SCHEDULE 13G/A: Baillie Gifford & Co. Discloses 10.1% Stake in Moderna, Inc. via Amended SEC Filing

Baillie Gifford & Co., a UK-based investment adviser, has filed an Amendment No. 4 to Schedule 13G, reporting a 10.1% beneficial ownership in Moderna, Inc. as of December 31, 2024.

Summary

• Baillie Gifford & Co., an investment adviser based in the United Kingdom, filed an Amendment No. 4 to Schedule 13G regarding its beneficial ownership in Moderna, Inc. Common Stock.
• As of December 31, 2024, Baillie Gifford & Co. beneficially owns an aggregate of 38,889,571 shares of Moderna, Inc. common stock.
• This ownership represents 10.1% of the class of Moderna's common stock.
• Baillie Gifford & Co. holds sole voting power over 31,423,042 shares and sole dispositive power over 38,889,571 shares.
• The shares are held on behalf of investment advisory clients, including investment companies, employee benefit plans, pension funds, or other institutional clients, in the ordinary course of business.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of Moderna, Inc.

Sentiment

Score: 5

Explanation: Neutral. The document is a factual disclosure of beneficial ownership, not a performance report or strategic announcement. The continued significant stake by a major investor is mildly positive, but the document itself doesn't convey strong sentiment regarding the company's operational or financial performance.

Positives

• A significant institutional investor, Baillie Gifford & Co., maintains a substantial 10.1% stake in Moderna, Inc., indicating continued confidence in the company.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, which can provide stability to the market.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Moderna's future performance or strategic direction, as it is a disclosure of beneficial ownership by an investor.

Industry Context

This filing reflects ongoing institutional investment activity within the biotechnology and pharmaceutical sectors, particularly in companies like Moderna that are at the forefront of mRNA technology. Baillie Gifford's continued significant stake underscores the long-term investment perspective often seen in growth-oriented sectors.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and stability by confirming continued institutional interest.

Key Dates

Keywords

Moderna, MRNA, Baillie Gifford, Schedule 13G, SEC filing, beneficial ownership, institutional investor, common stock, investment adviser